- Home
- FDMT vs HQL Comparison
FDMT vs HQL Comparison
Compare FDMT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDMT | HQL |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 689.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDMT | HQL |
|---|---|---|
| Price | $14.19 | $20.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $31.71 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 137.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | $25.75 |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $6.47 | $13.88 |
| 52 Week High | $16.93 | $22.67 |
Technical Indicators
Market Signals| Indicator | FDMT | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 44.12 |
| Support Level | $13.67 | $16.21 |
| Resistance Level | $16.93 | $21.32 |
| Average True Range (ATR) | 0.95 | 0.46 |
| MACD | -0.19 | -0.20 |
| Stochastic Oscillator | 15.87 | 5.59 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.